TRAX · Insider Trading
First Tracks Biotherapeutics, Inc. Ordinary Shares
Every open-market purchase and sale reported by TRAX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | John A Orwin | Director | M | +1,300 | — |
| 2026-09-04 | J. Anthony Ware | Director | MIXED | — | −$1.53M |
| 2026-08-18 | Benjamin Stone | Chief Business Officer | A | +60,492 deriv. | — |
| 2026-08-18 | Daniel Faga | President, CEO | A | +193,575 deriv. | — |
| 2026-08-18 | Paul F. Lizzul | Chief Medical Officer | A | +60,492 deriv. | — |
| 2026-08-05 | Daniel Faga | President, CEO | A | +193,576 deriv. | — |
| 2026-08-05 | Paul F. Lizzul | Chief Medical Officer | A | +60,492 deriv. | — |
| 2026-08-05 | Benjamin Stone | Chief Business Officer | A | +60,492 deriv. | — |
| 2026-06-17 | John P. Schmid | Director | M | +6,030 | — |
| 2026-06-17 | Rita Jain | Director | M | +7,330 | — |
| 2026-06-17 | Dennis M Fenton | Director | M | +6,030 | — |
| 2026-06-17 | John A Orwin | Director | M | +6,030 | — |
| 2026-06-17 | J. Anthony Ware | Director | M | +6,030 | — |
| 2026-06-17 | Magda Marquet | Director | M | +6,030 | — |
| 2026-06-12 | Rita Jain | Director | A | +9,500 deriv. | — |
| 2026-06-12 | Magda Marquet | Director | A | +9,500 deriv. | — |
| 2026-06-12 | John P. Schmid | Director | A | +9,500 deriv. | — |
| 2026-06-12 | John A Orwin | Director | A | +9,500 deriv. | — |
| 2026-06-12 | Dennis M Fenton | Director | A | +9,500 deriv. | — |
| 2026-06-12 | J. Anthony Ware | Director | A | +9,500 deriv. | — |
| 2026-05-14 | Dennis M Fenton | Director | A | +57,000 deriv. | — |
| 2026-05-14 | Ajim Tamboli | Chief Financial Officer | A | +18,600 deriv. | — |
| 2026-05-14 | J. Anthony Ware | Director | A | +57,000 deriv. | — |
| 2026-05-14 | John P. Schmid | Director | A | +57,000 deriv. | — |
| 2026-05-14 | Magda Marquet | Director | A | +57,000 deriv. | — |
| 2026-05-14 | Paul F. Lizzul | Chief Medical Officer | A | +99,000 deriv. | — |
| 2026-05-14 | Benjamin Stone | Chief Business Officer | A | +99,000 deriv. | — |
| 2026-05-14 | John A Orwin | Director | A | +57,000 deriv. | — |
| 2026-05-14 | Rita Jain | Director | A | +57,000 deriv. | — |
| 2026-05-14 | Daniel Faga | President, CEO | A | +371,300 deriv. | — |
| 2026-04-23 | Ajim Tamboli | Chief Financial Officer | A | +169,400 deriv. | — |
| 2026-04-22 | EcoR1 Capital, LLC | 10%+ Owner | Sell | +4,705,575 | +$65.00M |
| 2026-04-22 | ANAPTYSBIO, INC | 10%+ Owner | J | −100 | — |
| 2026-04-22 | John A Orwin | Director | A | — | — |
| 2026-04-22 | Dennis M Fenton | Director | A | — | — |
| 2026-04-22 | Daniel Faga | President, CEO | A | — | — |
| 2026-04-22 | Magda Marquet | Director | A | — | — |
| 2026-04-22 | Rita Jain | Director | A | — | — |
| 2026-04-22 | John P. Schmid | Director | A | — | — |
| 2026-04-22 | Paul F. Lizzul | Chief Medical Officer | A | — | — |
| 2026-04-22 | J. Anthony Ware | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| EcoR1 Capital, LLC | 10%+ Owner | 3,174,519 | $138.03M |
| Daniel Faga | President, CEO | 496,684 | $21.60M |
| Paul F. Lizzul | Chief Medical Officer | 42,669 | $1.86M |
| John P. Schmid | Director | 37,652 | $1.64M |
| Rita Jain | Director | 19,194 | $834.56K |
| John A Orwin | Director | 17,995 | $782.42K |
| Magda Marquet | Director | 15,960 | $693.94K |
| J. Anthony Ware | Director | 15,660 | $680.90K |
| Dennis M Fenton | Director | 10,995 | $478.06K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TRAX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.